Sort
39,280 grants matching “leukemia”
Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapies
$1,318,233Cynthia E Dunbar · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL
Protein Structure
$1,317,450Alexander Wlodawer · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
T-cell Transformation by Oncoviruses
$1,317,296Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Replication Dynamics in Patients on Suppressive Antiretroviral Therapy
$1,316,983Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Washington University/ Siteman Cancer Center Lead Academic Site
$1,316,888Nancy L Bartlett · Washington University · U10 · FY2017 · CA
Receptor -directed therapy
$1,314,117John Janik · Basic Sciences · Z01 · FY2007 · CA
Clinical Trials of Patients with AIDS-Related Malignancies
$1,313,488Robert Yarchoan · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Clinical Trials of Patients with AIDS-Related Malignancies
$1,313,319Robert Yarchoan · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
CPTR - Mass Spectrometry Unit
$1,313,080Lisa Jenkins · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
BMT Survivor Study-2 (BMTSS-2)
$1,312,128Smita Bhatia · University Of Alabama At Birmingham · U01 · FY2019 · CA
Regulation of innate lymphocyte function
$1,311,736Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Center
$1,310,938Sylvia Katina Plevritis · Stanford University · U54 · FY2012 · CA
Development of Recombinant Toxins to Treat Hematologic Malignancies
$1,310,387Robert Kreitman · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Architecture and Trajectory of Acquired Resistance to Therapy in AML
$1,308,998Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2022 · CA
Architecture and Trajectory of Acquired Resistance to Therapy in AML
$1,308,998Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2023 · CA
Architecture and Trajectory of Acquired Resistance to Therapy in AML
$1,308,996Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2025 · CA
Life and Longevity After Cancer (LILAC): The Women's Health Initiative Cancer Survivor Cohort
$1,308,977Garnet L. Anderson · Fred Hutchinson Cancer Center · U01 · FY2023 · CA
Cancer Prevention-Interception Against MGUS Progression
$1,308,925Yong Li · Baylor College Of Medicine · U54 · FY2025 · CA
Translation of Predictive Cancer Biomarkers into Clinical Practice
$1,308,910Timothy J. Triche · Children'S Hospital Of Los Angeles · RC2 · FY2010 · CA
Genetic Aspects Of Viral Oncogenesis In Inbred Strains and Wild Mouse Species
$1,308,492Christine Kozak · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
OSU as Network Lead Academic Participating Site for the NCI NCTN
$1,307,073Claire F Verschraegen · Ohio State University · U10 · FY2017 · CA
Washington University/Siteman Cancer Center Lead Academic Site
$1,307,056Nancy L Bartlett · Washington University · UG1 · FY2023 · CA
Development of Recombinant Toxins to Treat Hematologic Malignancies
$1,307,015Robert Kreitman · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Washington University/Siteman Cancer Center Lead Academic Site
$1,307,004Nancy L Bartlett · Washington University · UG1 · FY2022 · CA
ORGANOID-BASED MODELING AND THERAPEUTIC TARGETING OF TP53-MUTATED ACUTE MYELOID LEUKEMIA
$1,306,991The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2025 · Defense Health Agency